Format

Send to

Choose Destination
J Neurol Sci. 2013 Jan 15;324(1-2):38-9. doi: 10.1016/j.jns.2012.09.024. Epub 2012 Oct 2.

Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders.

Author information

1
Division of Neurology, Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.

Abstract

We evaluated the safety and efficacy of rituximab in seven Chinese patients with neuromyelitis optica (NMO) or neuromyelitis optica syndrome disorders (NMOSD) in a tertiary medical center in Hong Kong. After rituximab induction, five patients became relapse-free and two had 50% reduction of relapses over a median follow-up of 24 months. No further deterioration of functional status, measured by the Expanded Disability Status Scale, was observed in all patients. Infusions were well tolerated except in two patients who developed transient hypotension. Rituximab reduced clinical relapse and prevented neurological deterioration in a small cohort of Chinese patients with NMO or NMOSD.

PMID:
23040959
DOI:
10.1016/j.jns.2012.09.024
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center